UPCC 38424 Managed Access Program (MAP) Cohort Treatment Plan CCTL019B2003I to Provide Access for Patients with out of Specification Leukapheresis Product and/or out of Specification Manufactured Tisagenlecleucel (CTL019; Kymriah®)

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. The primary purpose of a MAP is to provide access to product. NA - No data will be entered into a clinical trial database

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 22 Apr 2026. Study ID: 24-1064
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator